^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Brinsupri (brensocatib)

    i
    Other names: INS1007, AZD7986, INS-1007, INS 1007, AZD 7986, AZD-7986
    Associations

    News

    Trials
    Company:
    AstraZeneca, Insmed
    Drug class:
    DPP1 inhibitor
    Associations

    News

    Trials
    1m
    CEDAR: A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) (clinicaltrials.gov)
    P2, N=214, Active, not recruiting, Insmed Incorporated | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Brinsupri (brensocatib)
    1m
    BiRCh: A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) (clinicaltrials.gov)
    P2, N=288, Completed, Insmed Incorporated | Active, not recruiting --> Completed
    Trial completion
    |
    Brinsupri (brensocatib)
    7ms
    BiRCh: A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) (clinicaltrials.gov)
    P2, N=288, Active, not recruiting, Insmed Incorporated | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Brinsupri (brensocatib)
    11ms
    Evaluation of Neutrophil Elastase Inhibitors as Potential Therapies for ELANE Associated Neutropenia. (PubMed, J Cell Immunol)
    In contrast, other NE inhibitors, i.e., sivelestat, BAY-678, and GW311616 and the DPP1 inhibitor, brensocatib, showed no effect on neutrophil differentiation. Molecular docking studies showed that MK0339 binds to an alternative site on the NE protein compared to other inhibitors with greater inhibitor-NE protein stability, suggesting a unique mechanism of action and supporting further investigation of MK0339 as a therapy for ELANE associated neutropenia.
    Journal
    |
    CD34 (CD34 molecule) • CD14 (CD14 Molecule) • ITGAM (Integrin, alpha M) • CEACAM8 (CEA Cell Adhesion Molecule 8)
    |
    Brinsupri (brensocatib)
    1year
    CEDAR: A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) (clinicaltrials.gov)
    P2, N=204, Recruiting, Insmed Incorporated | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Brinsupri (brensocatib)
    1year
    CEDAR: A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) (clinicaltrials.gov)
    P2, N=204, Not yet recruiting, Insmed Incorporated
    New P2 trial
    |
    Brinsupri (brensocatib)
    1year
    ASPEN: A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (clinicaltrials.gov)
    P3, N=1767, Completed, Insmed Incorporated | Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Oct 2024 | Trial primary completion date: Mar 2024 --> Oct 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Brinsupri (brensocatib)
    over1year
    Cathepsin C exacerbates EAE by promoting the expansion of Tfh cells and the formation of TLSs in the CNS. (PubMed, Brain Behav Immun)
    Conversely, treatment with AZD7986, a specific inhibitor of CatC, effectively attenuated the syndrome of EAE and its effects caused by CatC both in vivo and in vitro. These findings provide a novel insight into the critical role of CatC in innate and adaptive immunity in EAE, and specific inhibitor of CatC, AZD7986, may contribute to potential therapeutic strategies for MS.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    Brinsupri (brensocatib)
    over1year
    INS1007: A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants (clinicaltrials.gov)
    P1, N=24, Completed, Insmed Incorporated | Recruiting --> Completed
    Trial completion
    |
    Brinsupri (brensocatib)
    over1year
    INS1007: A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants (clinicaltrials.gov)
    P1, N=24, Recruiting, Insmed Incorporated | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Brinsupri (brensocatib)
    over1year
    INS1007: A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Insmed Incorporated
    New P1 trial
    |
    Brinsupri (brensocatib)
    almost2years
    A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants (clinicaltrials.gov)
    P1, N=20, Completed, Insmed Incorporated | Not yet recruiting --> Completed
    Trial completion
    |
    Brinsupri (brensocatib)